XVIVO Q2 sales rise 34%, beat estimates on thoracic strength

XVIVO reported a 34% increase in Q2 sales, surpassing market estimates due to strong performance in the thoracic segment. Following these results, AQ Group has raised its profit target for the period. The sales beat across the board has allowed the company to adjust its financial outlook upward, reflecting the growth achieved by XVIVO and the overall positive trajectory of the group's quarterly financial performance and strategic market strength.